Shun Minatsuki

Dr. Shun Minatsuki


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in International Heart Journal
Verified
Journal Article
Closed access
Shun MinatsukiShun Minatsuki
Shun Minatsuki
IMIchiro Miura
Ichiro Miura
AYAtsushi Yao
Atsushi Yao
HAHiroyuki Abe
Hiroyuki Abe
HMHironori Muraoka
Hironori Muraoka
IKIssei Komuro
Issei Komuro
Pulmonary hypertension (PH) induced by pulmonary tumor thrombotic microangiopathy (PTTM) can be fatal because its rapid progression confounds diagnosis, and it is difficult to control with therapy. Here we describe a woman with symptomatic PTTM-PH accompanying gastric cancer that was suspected from perfusion scintigraphy. PTTM-PH was diagnosed by gastroesophageal endoscopy and lung biopsy after partial control of PH using the platelet-derived growth factor (PDGF) receptor (PDGFR) tyrosine kinase inhibitor, imatinib. Treatment with sildenafil and ambrisentan further decreased PH, and she underwent total gastrectomy followed by adjuvant TS-1 chemotherapy. PH did not recur before her death from metastasis. Postmortem histopathology showed recanalized pulmonary arteries where the embolized cancer masses disappeared. PDGF-A, -B, and PDGFR-α, β expression was detected in cancer cells and proliferating pulmonary vascular endothelial cells. Thus, PTTM-PH was successfully controlled using a combination of imatinib, drugs to treat pulmonary arterial hypertension, and cancer management.

30 January 2024 in Circulation
Verified
Journal Article
Open access
KHKazuya Hosokawa
Kazuya Hosokawa
HWHiroko Watanabe
Hiroko Watanabe
YTYu Taniguchi
Yu Taniguchi
NINobutaka Ikeda
Nobutaka Ikeda
TITakumi Inami
Takumi Inami
OIon behalf of KABUKI Investigators
on behalf of KABUKI Investigators

1 February 2020 in Journal of Cardiology
Verified
Journal Article
Closed access
Shun MinatsukiShun Minatsuki
Shun Minatsuki
AKArihiro Kiyosue
Arihiro Kiyosue
SKSatoshi Kodera
Satoshi Kodera
THToru Hara
Toru Hara
ASAkihito Saito
Akihito Saito
IKIssei Komuro
Issei Komuro

7 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SISatoshi Ishii
Satoshi Ishii
Shun MinatsukiShun Minatsuki
Shun Minatsuki
MHMasaru Hatano
Masaru Hatano
ASAkihito Saito
Akihito Saito
HYHiroki Yagi
Hiroki Yagi
IKIssei Komuro
Issei Komuro
Lung transplantation (LT) is the only option for patients with pulmonary arterial hypertension (PAH) refractory to maximal medical therapy. However, some patients referred for LT could survive without LT, and its determinants remain unclear. This study aimed to elucidate prognostic factors of severe PAH at the referral time. We retrospectively analyzed 34 patients referred for LT evaluation. The primary outcome was a composite of death or LT. Over a median follow-up period of 2.56 years, eight patients received LT and eight died. Compared with LT-free survival group, pulmonary arterial systolic pressure (PASP) was higher (p = 0.042), and the ratio of tricuspid annular plane systolic excursion (TAPSE) to PASP (TAPSE/PASP) was lower (p = 0.01) in LT or death group. In receiver operating characteristic analysis, the area under the curve was 0.759 (95% confidence interval 0.589–0.929) for TAPSE/PASP to predict primary outcome, and the optimal cut-off value was 0.30 mm/mmHg (sensitivity 0.875 and specificity 0.667). In a multivariate analysis, TAPSE/PASP was independently associated with death or LT. Kaplan–Meier analysis showed a better LT-free survival in patients with TAPSE/PASP ≧0.30 mm/mmHg than in those with < 0.30 mm/mmHg (p = 0.001). Low-level TAPSE/PASP could be a poor prognostic factor in PAH patients referred for LT evaluation.

1 August 2020 in Journal of Cardiology
Verified
Journal Article
Closed access
Shun MinatsukiShun Minatsuki
Shun Minatsuki
SKSatoshi Kodera
Satoshi Kodera
AKArihiro Kiyosue
Arihiro Kiyosue
ASAkihito Saito
Akihito Saito
HMHisataka Maki
Hisataka Maki
IKIssei Komuro
Issei Komuro

27 September 2019 in International Heart Journal
Verified
Journal Article
Open access
PDF file
Shun MinatsukiShun Minatsuki
Shun Minatsuki
MHMasaru Hatano
Masaru Hatano
HMHisataka Maki
Hisataka Maki
ETEiki Takimoto
Eiki Takimoto
HMHiroyuki Morita
Hiroyuki Morita
IKIssei Komuro
Issei Komuro
Current therapeutic methods for chronic thromboembolic pulmonary hypertension (CTEPH) can improve hemodynamic status and are expected to improve prognoses. However, some patients experience dyspnea during effort and continue supplemental oxygenation despite their hemodynamic status being fully improved. Considering the pathogenesis of CTEPH, the dead space and intrapulmonary shunt are assumed to be responsible for hypoxia in CTEPH, but their contributions are unclear. It is also unclear whether they are improved after treatment. The aim of this study was to investigate the implications of the dead space ratio (DSR) and the intrapulmonary shunt ratio (ISR) for hypoxia in CTEPH and treatment for CTEPH.We retrospectively measured the DSR and ISR of 23 consecutive patients with CTEPH. For 11 of these 23 (10 were treated by balloon pulmonary angioplasty, one with riociguat), we also measured these parameters before and after CTEPH treatments. Overall, the DSR and ISR were abnormally elevated (DSR: 0.63 ± 0.06; ISR: 0.25 ± 0.05). After treatment, mean pulmonary artery pressure was improved (from 40.2 ± 8.1 to 25.5 ± 2.7 mmHg). Although atrial oxygen saturation (SaO2), DSR and ISR were improved (SaO2: from 90.2 ± 3.2 to 93.7 ± 1.8%; DSR: from 0.64 ± 0.06 to 0.58 ± 0.04; ISR: from 0.20 ± 0.04 to 0.17 ± 0.02), these improvements were slight compared with that of mean pulmonary artery pressure.The DSR and ISR were abnormally elevated in patients with CTEPH and their improvement by treatment was limited. Only DSR can be a useful marker for normalization of hypoxia in CTEPH.